Peak Asset Management LLC Purchases New Stake in Stryker Corporation $SYK

Peak Asset Management LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 52,332 shares of the medical technology company’s stock, valued at approximately $16,476,000. Stryker makes up 2.4% of Peak Asset Management LLC’s portfolio, making the stock its 15th largest holding.

Several other large investors have also modified their holdings of SYK. Gables Capital Management Inc. bought a new stake in shares of Stryker in the 2nd quarter valued at approximately $25,000. Kilter Group LLC acquired a new stake in Stryker during the second quarter worth about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter worth about $26,000. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. Finally, Compass Financial Management LLC bought a new position in shares of Stryker during the second quarter valued at approximately $27,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.5%

Shares of SYK stock opened at $327.80 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business’s fifty day moving average is $327.39 and its 200-day moving average is $332.16. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The stock has a market cap of $125.73 billion, a PE ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a report on Friday, May 1st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Royal Bank Of Canada decreased their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 355,370 shares of company stock worth $119,447,201. Insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.